CABA

CABA

USD

Cabaletta Bio Inc. Common Stock

$2.700-0.160 (-5.594%)

实时价格

Healthcare
生物技术
美国

价格图表

Loading Chart...

关键指标

市场指标
公司基本面
交易统计

市场指标

开盘价

$2.860

最高价

$2.970

最低价

$2.630

成交量

3.67M

公司基本面

市值

247.0M

所属行业

生物技术

国家/地区

United States

交易统计

平均成交量

3.63M

交易所

NMS

货币

USD

52周价格范围

最低价 $0.986当前价 $2.700最高价 $5.46

相关新闻

GlobeNewswire

Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update

Rese-cel data presented at multiple medical meetings demonstrated potentially transformative, drug-free clinical responses with a favorable safety profile for autoimmune patients supporting outpatient use All myositis

查看更多
Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update
Analyst Upgrades

FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy

William Blair notes FDA's tougher stance on gene therapy programs as AMT-130 faces uncertainty in its accelerated approval timeline.

查看更多
FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy
Analyst Upgrades

Cantor Fitzgerald Maintains Overweight on Cabaletta Bio, Raises Price Target to $30

Cantor Fitzgerald analyst Josh Schimmer maintains Cabaletta Bio with a Overweight and raises the price target from $15 to $30.

查看更多
Cantor Fitzgerald Maintains Overweight on Cabaletta Bio, Raises Price Target to $30
GlobeNewswire

Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025

– All myositis patients in the Phase 1/2 DM/ASyS cohort with sufficient follow-up who met key registrational inclusion criteria exceeded the registrational primary endpoint, demonstrating major TIS responses with no

查看更多
Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025